SHILPAMEDShilpa Medicare Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · India Ratings: A+ (Stable)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 0.2 this quarter.
Momentum from moving averages, Supertrend and RSI.
2 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
2 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹529 Cr | ₹79 Cr | 20.43% | 14.97% | ₹4.05 | 9.2x |
| Q1 FY2027 | ₹466 Cr | ₹101 Cr | 21.70% | 21.66% | ₹5.16 | 8.6x |
| Q4 FY2026 | ₹437 Cr | ₹108 Cr | 20.39% | 24.67% | ₹5.51 | 9.8x |
| Q3 FY2026 | ₹410 Cr | ₹45 Cr | 20.49% | 10.88% | ₹2.36 | 6.7x |
| Q2 FY2026 | ₹370 Cr | ₹44 Cr | 21.21% | 11.91% | ₹2.25 | 5.1x |
| Q1 FY2026 | ₹321 Cr | ₹47 Cr | 19.51% | 14.59% | ₹2.40 | 3.7x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.